Fuel Tech, Inc. (NASDAQ:FTEK)
Fuel Tech, Inc. (NASDAQ:FTEK) represented a move of 0 percent or $-0.05 per share and closed its previous day trading session at $1.3. 0 Shares were traded in the last trading session with an Average Volume of 64.47 Million Shares. The stock currently has a Market Capitalization of 33.2 Million.
Fuel Tech is a leading technology company engaged in the worldwide development, commercialization and application of state-of-the-art proprietary technologies for air pollution control, process optimization, and advanced engineering services. These technologies enable customers to produce both energy and processed materials in a cost-effective and environmentally sustainable manner. The Company’s nitrogen oxide reduction technologies include the NOxOUT, NOxOUT CASCADE, NOxOUT ULTRA, Rich Reagent Injection and NOxOUT-SCR processes. These technologies have established Fuel Tech as a leader in post-combustion NOx control systems, with installations on worldwide, where coal, municipal waste, biomass, and other fuels are utilized. The Company’s FUEL CHEM technology revolves around the unique application of chemicals to improve the efficiency and reliability of combustion units by controlling slagging, fouling, corrosion and opacity.
The stock traded between $0.92 and $1.83 over 1-Year time period showing its price to sales ratio of 0.61. Fuel Tech, Inc. (NASDAQ:FTEK) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $2.15 and 200-Day Simple Moving Average of $8.45. Its Price to Free Cash Flow is 0 and Price to Book of 0.94.
Analyst’s recommended the stock as 3 where 1 represents Strong Buy and 5 represents Sell.
Recro Pharma, Inc. (NASDAQ:REPH)
In the last trading session, Recro Pharma, Inc. (NASDAQ:REPH) added its value by 0% closing at the price of $7.07. The stock currently has market capitalization of 156.25 Million, with average volume of 181.19 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Recro Pharma, Inc. (NASDAQ:REPH) is showing beta of -0.51. This particular value of beta suggests that Recro Pharma, Inc. (NASDAQ:REPH) has historically moved -51% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Recro Pharma, Inc. (NASDAQ:REPH) is at $-2.76.
The stock currently has RSI of 55.49. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.
Recro Pharma, Inc. (NASDAQ:REPH) topped its 52-week high price of $13.05 on 05/23/18 and 52-Week Low Price of $ 4.78 on 06/29/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 4.37% and monthly volatility of 5.02% respectively.